The local medical sector is buzzing with the arrival of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist showing impressive results in early trials for managing obesity. This medication https://johsocial.com/story12460212/retatrutide-australia-australia-a-emerging-hope-for-weight-loss